Drug intelligence / Profile preview

Coldamaris Junior

Development stage: Unknown
Lead developer: Sigmapharm Arzneimittel
Modality: Small Molecules
Administration: Intranasal, Topical

Overview

Coldamaris Junior is a preservative-free nasal and throat spray developed by Sigmapharm Arzneimittel. It is formulated as an isotonic sodium chloride solution containing 2% dexpanthenol. The medical device is designed to keep the nasal and pharyngeal mucosae moist, with dexpanthenol providing additional care and protection for the mucous membranes. It is indicated for the moistening of dry or encrusted nasal and pharyngeal mucosa, as a supportive treatment for the common cold or allergic rhinitis, and as a supplementary treatment alongside decongestant medications. It features a child-friendly spray jet and is suitable for children, adolescents, and adults.

Brand names: Coldamaris Junior
Other names: Coldamaris Junior Nasal and Throat SprayColdamaris Junior Nasen- und Rachenspray

Beyond the preview

Go deeper on Coldamaris Junior.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coldamaris Junior.